Currently available vaccines for the prevention of seasonal influenza virus infection have limited ability to induce immunity against diverse H3N2 viruses, an influenza A subtype that has led to high morbidity and mortality in recent years. Now, scientists have engineered a synthetic DNA vaccine shown to produce broad immune responses against these H3N2 viruses.